Time truly flies! We are thrilled to announce the celebration of infuse Life Science's 1st anniversary on October 1st. We are steadily approaching the realization of the vision we promised that day: to use the power of life science to solve Japan and the world's demographic challenges, particularly the declining birthrate.

This report details our progress over the nine months leading up to this milestone.

1. Research & Development in Ob-Gyn

The planned functional prototype has been successfully completed and is now in excellent operational condition. We are developing a specialized, multi-product lineup focused on the vital yet often underfunded field of Ob-Gyn—a market deemed small but highly significant, often overlooked by larger corporations.

This prototype represents a crucial step in our strategy to expand our offerings across the entire clinical pathway: observation, examination, diagnosis, and ultimately, treatment.

Based on this successful result, we have initiated collaboration discussions with several key investors and medical device manufacturers, receiving overwhelmingly positive feedback and strong indications of interest from nearly all parties. The next phase involves transitioning to final product development, operating under a robust QSR/QMS/ISO13485 level.

2. Consulting Business

As detailed on the Services page of our website, our business model education and consulting services continue to be highly regarded. We encourage you to read the testimonials and contact us today. We promise to provide proposals—in terms of content and pricing—that are precisely aligned with your company's specific needs and demands.

3. Staff Recruitment

As we enter this critical new phase of growth and development, we are actively seeking passionate staff members. Join us in the fight against global and domestic demographic challenges, leveraging cutting-edge medical devices to address the declining birthrate. We need your skills and dedication to stand with us.

While we enjoy the arrival of autumn, we are also mindful of the intense spread of infectious diseases. We wish everyone good health and continued well-being.

The devices are not approved as medical device. These are aiming at introducing our business to the investors, but not intend to show to the medical professionals or patients.

Seven months have passed since our incorporation last December, and we are pleased to report significant progress. In these complex times, our company and every one of our employees are working diligently toward a new dimension of medicine that no one has yet explored.

Here are the two key updates on our business activities for the second quarter.

1. R&D in the Obstetrics and Gynecology Field

We were aiming to complete our prototype by the end of June. However, due to a delay in procuring some components and the development of new features and patentable inventions, the prototype was finalized at the end of July. We expect to complete all non-clinical evaluations by mid-August. While there has been a slight delay, we consider it a positive one that will benefit our future endeavors.

2. Consulting Business

Thanks to the strong reception, we now have six projects running simultaneously, starting with our very first client. We've also begun negotiations with potential clients in the drug discovery field, aiming to diversify our services. Furthermore, we've received an order from a client in India, which is helping us to further our international expansion.

Japan is currently experiencing a severe heatwave.

Please take care of yourselves.

The devices are not approved as medical device. These are aiming at introducing our business to the investors, but not intend to show to the medical professionals or patients.

Tokyo, Japan – [February 20th, 2025] – infuse Life Science, Inc. has been selected for a grant for the Reiwa 6th (Fiscal Year 2024) Femtech Development Support and Promotion Project by The Tokyo Metropolitan Small and Medium Enterprise Support Center.

This grant will be used to further develop our innovative ob-gyn diagnostic medical device, which aims to improve the current standard of care by replacing radiology-based methods and enhancing women's lives.

Dai Saito, CEO of infuse Life Science, Inc., expressed his enthusiasm for being selected for this prestigious project. "We are committed to diligently working to bring our product to market as soon as possible, thereby contributing to improved women's healthcare," said Saito.

infuse Life Science, Inc., a pioneering research-driven startup focused on revolutionizing the life sciences for the Ob-GYN healthcare industry, today announced that it has been selected as a finalist of the Tokyo SME grant. This grant will support the development of the company's second product, which follows its previously Tokyo SME grant-selected diagnostic method.

The selection is an important step to the company's commitment to innovation and its strong track record in research and development. This latest product, combined with our existing diagnostic solution, will enable us to offer a comprehensive suite of products to address unmet needs in the life sciences field.

“This notification of grant approval is a testament to the broader understanding of our vision beyond a single product, but as a comprehensive solution,” said Dai Saito, CEO of infuse Life Science, Inc. “We are committed to working diligently to bring these products to clinical implementation as soon as possible.”

We are pleased to announce that we have officially become a corporation and are embarking on a new chapter of growth. Concurrently, we are thrilled to welcome Dr. Yukio Suzuki as our new Chief Medical Officer and Co-Founder.

As a corporation, we will be able to accelerate our business initiatives and pursue our vision to provide innovative breakthrough methods in Ob-Gyn medical solutions. By focusing on developping technology in women's health, we aim to achieve continuous growth of the business and drive sustainable world population issues.

Under Dr. Suzuki's leadership in our medical affiars, we will expedite the Ob-Gyn medical products R&D and clinical evaluation to strengthen and expand our business pipeline.

We are committed to providing innovative solutions to address the critical issue of women's health. We appreciate your continued support.